Topical Delgocitinib Effective for Hand Eczema in Phase 3 Trial Topical Delgocitinib Effective for Hand Eczema in Phase 3 Trial

The phase 3 study evaluated delgocitinib, an investigational topical pan-JAK inhibitor that inhibits activation of the JAK-STAT pathway and targets key mediators of chronic hand eczema.MDedge News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Source Type: news